Synaptic vesicle glycoprotein 2C (SV2C) modulates dopamine release and is disrupted in Parkinson’s disease

The synaptic vesicle glycoprotein 2 (SV2) family of proteins are involved in synaptic function throughout the brain. The ubiquitously expressed SV2A has been widely implicated in epilepsy, though SV2C with its restricted basal ganglia distribution has no known function. SV2C is emerging as a potentially relevant protein in Parkinson’s disease, as it is a genetic modifier of nicotine neuroprotection and sensitivity to L-DOPA. Here we identify SV2C as a mediator of dopamine homeostasis and report that disrupted expression of SV2C within the basal ganglia is a pathological feature of Parkinson’s disease (PD). Genetic deletion of SV2C leads to reduced dopamine release in the dorsal striatum as measured by fast-scan cyclic voltammetry, reduced striatal dopamine content, disrupted alpha-synuclein expression, deficits in motor function, and alterations in neurochemical effects of nicotine. Further, SV2C expression is dramatically altered in postmortem brain tissue from PD cases, but not in Alzheimer’s disease, progressive supranuclear palsy or multiple system atrophy. This disruption was paralleled in mice overexpressing mutated α-synuclein. These data establish SV2C as a novel mediator of dopamine neuron function and suggest that SV2C disruption is a unique feature of PD that likely contributes to dopaminergic dysfunction

[1]  Houeto Jean-Luc.  [Parkinson's disease]. , 2022, La Revue du praticien.

[2]  Alison I. Bernstein,et al.  Vesicular Monoamine Transporter 2 (VMAT2) Level Regulates MPTP Vulnerability and Clearance of Excess Dopamine in Mouse Striatal Terminals. , 2016, Toxicological sciences : an official journal of the Society of Toxicology.

[3]  M. Hutz,et al.  Influence of genetic, biological and pharmacological factors on levodopa dose in Parkinson's disease. , 2016, Pharmacogenomics.

[4]  R. Jaenisch,et al.  Corrigendum: Parkinson-causing α-synuclein missense mutations shift native tetramers to monomers as a mechanism for disease initiation , 2015, Nature Communications.

[5]  Laura M. Vecchio,et al.  Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo , 2014, Proceedings of the National Academy of Sciences.

[6]  C. Cavada,et al.  Is Parkinson's Disease a Vesicular Dopamine Storage Disorder? Evidence from a Study in Isolated Synaptic Vesicles of Human and Nonhuman Primate Striatum , 2014, The Journal of Neuroscience.

[7]  E. Fedele,et al.  LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex , 2014, Front. Mol. Neurosci..

[8]  G. Miller,et al.  Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus , 2014, Neuropharmacology.

[9]  Vladimir Makarov,et al.  The Sac1 Domain of SYNJ1 Identified Mutated in a Family with Early‐Onset Progressive Parkinsonism with Generalized Seizures , 2013, Human mutation.

[10]  D. Mash,et al.  Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease , 2013, Journal of neurochemistry.

[11]  J. Jung,et al.  Alignment of Synaptic Vesicle Macromolecules with the Macromolecules in Active Zone Material that Direct Vesicle Docking , 2013, PloS one.

[12]  S. Goldwurm,et al.  Analysis of vesicular monoamine transporter 2 polymorphisms in Parkinson’s disease , 2013, Neurobiology of Aging.

[13]  S. Schiffmann,et al.  A role for Sv2c in basal ganglia functions , 2013, Brain Research.

[14]  J. Rilstone,et al.  Brain dopamine-serotonin vesicular transport disease and its treatment. , 2013, The New England journal of medicine.

[15]  E. Belluzzi,et al.  Presynaptic dysfunction in Parkinson's disease: a focus on LRRK2. , 2012, Biochemical Society transactions.

[16]  S. Factor,et al.  A genetic basis for the variable effect of smoking/nicotine on Parkinson's disease , 2012, The Pharmacogenomics Journal.

[17]  Benjamin J. Whalley,et al.  The Synaptic Vesicle Glycoprotein 2A Ligand Levetiracetam Inhibits Presynaptic Ca2+ Channels through an Intracellular Pathway , 2012, Molecular Pharmacology.

[18]  D. Lovinger,et al.  Conditional Expression of Parkinson's Disease-Related Mutant α-Synuclein in the Midbrain Dopaminergic Neurons Causes Progressive Neurodegeneration and Degradation of Transcription Factor Nuclear Receptor Related 1 , 2012, The Journal of Neuroscience.

[19]  Toru Yamashita,et al.  Alternative α-synuclein transcript usage as a convergent mechanism in Parkinson's disease pathology , 2012, Nature Communications.

[20]  Amy L. Nowack,et al.  Levetiracetam Reverses Synaptic Deficits Produced by Overexpression of SV2A , 2011, PloS one.

[21]  J. Harrow,et al.  A conditional knockout resource for the genome-wide study of mouse gene function , 2011, Nature.

[22]  Richard Wade-Martins,et al.  Functional Alterations to the Nigrostriatal System in Mice Lacking All Three Members of the Synuclein Family , 2011, The Journal of Neuroscience.

[23]  G. Miller,et al.  VMAT2-Deficient Mice Display Nigral and Extranigral Pathology and Motor and Nonmotor Symptoms of Parkinson's Disease , 2011, Parkinson's disease.

[24]  W. Wurst,et al.  LRRK2 Controls Synaptic Vesicle Storage and Mobilization within the Recycling Pool , 2011, The Journal of Neuroscience.

[25]  S. Schiffmann,et al.  Distribution of SV2C mRNA and protein expression in the mouse brain with a particular emphasis on the basal ganglia system , 2011, Brain Research.

[26]  Amy L. Nowack,et al.  SV2 regulates neurotransmitter release via multiple mechanisms. , 2010, American journal of physiology. Cell physiology.

[27]  Zhen-Yu Zhou,et al.  SV2 Acts via Presynaptic Calcium to Regulate Neurotransmitter Release , 2010, Neuron.

[28]  David R. Brown.  Oligomeric alpha‐synuclein and its role in neuronal death , 2010, IUBMB life.

[29]  Amy L. Nowack,et al.  Cotrafficking of SV2 and Synaptotagmin at the Synapse , 2010, The Journal of Neuroscience.

[30]  G. Miller,et al.  Nonmotor Symptoms of Parkinson's Disease Revealed in an Animal Model with Reduced Monoamine Storage Capacity , 2009, The Journal of Neuroscience.

[31]  D. Sulzer,et al.  Interplay between Cytosolic Dopamine, Calcium, and α-Synuclein Causes Selective Death of Substantia Nigra Neurons , 2009, Neuron.

[32]  J. Vautrin.  SV2 frustrating exocytosis at the semi‐diffusor synapse , 2009, Synapse.

[33]  T. Südhof,et al.  SV2 Renders Primed Synaptic Vesicles Competent for Ca2+-Induced Exocytosis , 2009, The Journal of Neuroscience.

[34]  P. Emson,et al.  Reduced vesicular storage of dopamine exacerbates methamphetamine‐induced neurodegeneration and astrogliosis , 2008, Journal of neurochemistry.

[35]  Gary W. Miller,et al.  Reduced Vesicular Storage of Dopamine Causes Progressive Nigrostriatal Neurodegeneration , 2007, The Journal of Neuroscience.

[36]  R. Roberts,et al.  Basal ganglia dopamine loss due to defect in purine recycling , 2007, Neurobiology of Disease.

[37]  E. Tolosa,et al.  G2019S LRRK2 mutation causing Parkinson’s disease without Lewy bodies , 2007, Journal of Neurology, Neurosurgery & Psychiatry.

[38]  G. Miller,et al.  Polychlorinated biphenyl-induced reduction of dopamine transporter expression as a precursor to Parkinson's disease-associated dopamine toxicity. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.

[39]  Eric A. Johnson,et al.  SV2 Is the Protein Receptor for Botulinum Neurotoxin A , 2006, Science.

[40]  B. Davletov,et al.  The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves , 2006, FEBS Letters.

[41]  Beate Ritz,et al.  Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women. , 2006, Human molecular genetics.

[42]  S. Theander,et al.  SV2A and SV2C are not vesicular Ca2+ transporters but control glucose-evoked granule recruitment , 2005, Journal of Cell Science.

[43]  Kazuko Hasegawa,et al.  An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family , 2005, Annals of neurology.

[44]  S. Mochida,et al.  SV2A and SV2C contain a unique synaptotagmin-binding site , 2005, Molecular and Cellular Neuroscience.

[45]  T. Dawson,et al.  Absence of inclusion body formation in the MPTP mouse model of Parkinson's disease. , 2005, Brain research. Molecular brain research.

[46]  R. Janz,et al.  SV2B Regulates Synaptotagmin 1 by Direct Interaction* , 2004, Journal of Biological Chemistry.

[47]  K. Nocka,et al.  The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[48]  S. Cragg,et al.  Nicotine amplifies reward-related dopamine signals in striatum , 2004, Nature Neuroscience.

[49]  D. Sulzer,et al.  Frequency-dependent modulation of dopamine release by nicotine , 2004, Nature Neuroscience.

[50]  P. K. Gangopadhaya,et al.  Parkinsonism plus syndrome--a review. , 2003, Neurology India.

[51]  P. Gorostiza,et al.  Control of neurotransmitter release by an internal gel matrix in synaptic vesicles , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[52]  G. Miller,et al.  Detection of Behavioral Impairments Correlated to Neurochemical Deficits in Mice Treated with Moderate Doses of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine , 2002, Experimental Neurology.

[53]  Miguel A Hernán,et al.  A meta‐analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease , 2002, Annals of neurology.

[54]  P. Lansbury,et al.  Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. , 2002, Biochemistry.

[55]  P. M. Chan,et al.  Mice with Very Low Expression of the Vesicular Monoamine Transporter 2 Gene Survive into Adulthood: Potential Mouse Model for Parkinsonism , 2001, Molecular and Cellular Biology.

[56]  Tao Xu,et al.  SV2 modulates the size of the readily releasable pool of secretory vesicles , 2001, Nature Cell Biology.

[57]  Z. Szilvássy,et al.  Nitric Oxide, Peroxynitrite and cGMP in Atherosclerosis-Induced Hypertension in Rabbits: Beneficial Effects of Cicletanine , 2001, Journal of Vascular Research.

[58]  Brian D. Hale,et al.  Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[59]  J. Buhler,et al.  Serial microanalysis of renal transcriptomes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[60]  R Janz,et al.  SV2C is a synaptic vesicle protein with an unusually restricted localization: anatomy of a synaptic vesicle protein family , 1999, Neuroscience.

[61]  E. Pothos,et al.  Vesicular Transport Regulates Monoamine Storage and Release but Is Not Essential for Amphetamine Action , 1997, Neuron.

[62]  Y. Glinka,et al.  Dopamine Neurotoxicity: Inhibition of Mitochondrial Respiration , 1995, Journal of neurochemistry.

[63]  K. Seppi,et al.  Nonmotor symptoms in Parkinson's , 2013 .

[64]  Patrik Brundin,et al.  Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. , 2002, Nature reviews. Neuroscience.

[65]  J. Fielding,et al.  Propofol Sedation for Oesophago-Gastro-Duodenoscopy , 1999, Diagnostic and Therapeutic Endoscopy.

[66]  K. Hasegawa,et al.  Autosomal dominant familial Parkinson disease: older onset of age, and good response to levodopa therapy. , 1997, European neurology.

[67]  G. Miller,et al.  VMAT2-Deficient Mice Display Nigral and Extranigral Pathology and Motor and Nonmotor Symptoms of Parkinson's Disease , 2011, Parkinson's disease.